Puma Biotechnology | PBYI - Gross Profit On Sales

Stock Price
6.33
Daily Change
0.07 1.12%
Monthly
-16.71%
Yearly
102.24%
Q1 Forecast
5.94

Puma Biotechnology reported $20.32M in Gross Profit on Sales for its fiscal quarter ending in September of 2024.





Gross Profit On Sales Change Date
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amgen USD 6.48B 307M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Exelixis USD 572.18M 7M Dec/2025
Gilead Sciences USD 6.31B 106M Dec/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Incyte USD 1.39B 118.68M Dec/2025
MacroGenics USD 31.11M 30.14M Dec/2025
Moderna USD 226M 583M Dec/2025
Novartis USD 10.25B 570M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
Takeda JPY 790.55B 262.97B Dec/2025
TG Therapeutics USD 154.43M 20.81M Dec/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025